Physician profile
Cory E Declue
NPI 1023660115
$2,871.43
in general payments reported to CMS, 2019-2025
25 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $138 · 2024: $342 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643 · Education: $90.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.03 |
| Education | $90.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $482.86 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $340.11 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $336.52 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $203.61 | 2024-2025 | Ozempic, Rybelsus, Tresiba |
| Sequel Med Tech, LLC | $193.09 | 2025 | Twiist |
| Amgen INC. | $180.01 | 2024-2025 | Evenity, Tepezza, Prolia |
| Glaxosmithkline, LLC. | $137.88 | 2022 | |
| Tandem Diabetes Care, INC. | $134.31 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $126.81 | 2025 | Minimed 780g |
| Beta Bionics, INC. | $112.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $104.06 | 2025 | Licart, Flector, Tirosint |
| Kvk-Tech, INC. | $99.83 | 2025 | |
| Ascendis Pharma Endocrinology INC | $88.93 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $64.83 | 2024-2025 | |
| Alvogen INC | $57.44 | 2025 | Teriparatide |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $42.77 | 2025 | Unithroid |
| Insulet Corporation | $35.47 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $20.83 | 2025 | |
| Mannkind Corporation | $19.34 | 2025 | |
| Dexcom, INC. | $19.15 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.73 | 2025 | |
| Abbvie INC. | $16.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2024 | Jardiance |
| Evoke Pharma, INC. | $14.81 | 2025 | |
| Cequr Corporation | $8.87 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Declue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.